Moderna, Inc.
The article says reported Lyme disease cases in Canada rose from 144 in 2009 to 5,809 in 2024, with 2025 preliminary cases at 7,105, citing PHAC data. It notes no human Lyme vaccine is currently approved. It describes Pfizer and Valneva’s co-developed vaccine PF-07307405 completing Phase 3 as of March 2026, and Moderna’s mRNA-1975 and mRNA-1982 in Phase 2.
On Aug. 5, the FDA approved Moderna’s mRNA influenza vaccine, mFlusiva, for adults 50 and up, with U.S. pharmacy availability expected for the 2026-2027 flu season. In a trial of 40,000+ adults ages 50-64, it reduced flu risk by 27% versus standard shots but caused more side effects. FDA approval for 65+ is accelerated pending further comparisons.
The FDA approved Moderna’s mRNA flu vaccine mFLUSIVA for adults over 50, citing documented superiority versus standard-dose flu vaccines. Moderna said it is about 27% more effective. The article says mRNA production avoids egg-based manufacturing, enabling faster updates to emerging strains. It also notes prior FDA review delays and vaccine skepticism.
Over the past 7 days, alphai's AI scored 15 news stories mentioning MRNA (Moderna, Inc.). Coverage has skewed bullish: 12 bullish, 3 neutral, and 0 bearish.
Recent MRNA coverage spans regulation, technology and financial news.
In the last 30 days, MRNA insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($28.7M). The most active reporter was Bancel Stephane, Chief Executive Officer, with 4 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Phase 2 status for two separate Lyme candidates supports continued R&D optionality, but it is less immediate than Phase 3.
Approval expands Moderna’s vaccine franchise and creates near-term demand expectations for the 2026-2027 flu season, tempered by higher reported side effects and mRNA skepticism.
Regulatory approval of a new, faster-to-produce mRNA flu product is a meaningful positive catalyst for Moderna’s near-term commercialization outlook and sentiment around its mRNA platform.
Regulatory approval and trial efficacy details are a concrete catalyst for Moderna’s flu franchise and near-term sentiment.
FDA approval should improve Moderna’s near-term commercialization outlook for an mRNA flu franchise and reduce regulatory overhang.
alphai scores every news story that mentions MRNA with an AI model for sentiment and relevance, and aggregates insider trades from Moderna, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
The article says reported Lyme disease cases in Canada rose from 144 in 2009 to 5,809 in 2024, with 2025 preliminary cases at 7,105, citing PHAC data. It notes no human Lyme vaccine is currently approved. It describes Pfizer and Valneva’s co-developed vaccine PF-07307405 completing Phase 3 as of March 2026, and Moderna’s mRNA-1975 and mRNA-1982 in Phase 2.
6 min readOn Aug. 5, the FDA approved Moderna’s mRNA influenza vaccine, mFlusiva, for adults 50 and up, with U.S. pharmacy availability expected for the 2026-2027 flu season. In a trial of 40,000+ adults ages 50-64, it reduced flu risk by 27% versus standard shots but caused more side effects. FDA approval for 65+ is accelerated pending further comparisons.
6 min readThe FDA approved Moderna’s mRNA flu vaccine mFLUSIVA for adults over 50, citing documented superiority versus standard-dose flu vaccines. Moderna said it is about 27% more effective. The article says mRNA production avoids egg-based manufacturing, enabling faster updates to emerging strains. It also notes prior FDA review delays and vaccine skepticism.
6 min readThe article reviews health headlines. It says Trump signed an executive order to further review and potentially split the MMR vaccine into separate shots, but states still set school vaccine requirements. It notes CDC-reported Candida auris cases exceed 3,000 this year. It reports FDA approval of Moderna’s mRNA flu vaccine mFlusiva for adults 50-64, about 27% more effective. It also covers FDA approval of Tudriqev, a genetically modified herpes virus for advanced melanoma.
5 min readABC News reports that the FDA has approved Moderna’s first mRNA flu vaccine, according to Dr. Tara Narula. The approval makes Moderna’s product the first-ever mRNA flu shot from the company, which could affect investor expectations for its vaccine pipeline and future sales.
2 min readThe FDA approved Moderna’s mRNA influenza vaccine mFlusiva for adults 50 and older. Adults 50 to 64 received standard approval based on efficacy, with 26.6% reported efficacy versus a licensed standard-dose flu vaccine. Adults 65+ received accelerated approval based on antibody response, contingent on a confirmatory postmarketing trial over two flu seasons. Availability depends on supply and ACIP recommendations.
6 min readArbutus Biopharma (ABUS) received about $178 million from Moderna (MRNA) as its share of a $950 million noncontingent LNP patent settlement, with reimbursement of legal costs and an expected Q3 dividend tied to Genevant. ABUS reported Q1 2026 revenue of $179.1 million and net income of $169.7 million. Moderna reported Q2 2026 revenue of $145 million and a net loss of $782 million, plus FDA approval for mFLUSIVA.
6 min readA roundup of Q2 earnings trends for major pharma and biotech firms highlights GLP-1 marketing spend, biosimilar and generic competition, and China-related risks. Eli Lilly raised Q2 marketing expenses 25% to $3.43B and lifted year-end revenue guidance to $85B-$87B. Novo Nordisk reported 5M Wegovy pill prescriptions in 30 weeks. Pfizer cut promotional costs and plans $2.5B savings (2027-29).
7 min readModerna said the FDA approved its mRNA flu vaccine mRNA-1010 (mFLUSIVA) for adults 50 to 64, after a unanimous VRBPAC vote. Phase III data showed favorable safety and 26.6% higher efficacy versus the standard flu shot, with similar serious adverse events. Europe, Canada, and Australia reviews are pending.
7 min readHealth Canada authorized Moderna (MRNA) to start a Phase I trial in Canada for its Bundibugyo Ebola mRNA vaccine candidate, following U.K. clearance. The trial is intended to assess safety, dosing, and immune response. The article links the approval to Moderna’s pipeline diversification and reiterates 2026 revenue guidance of up to 10% growth.
6 min read
